In the evolving landscape of analytical chemistry, the shift from "bulk" to "single-cell" analysis represents more than just a change in scale—it is a fundamental shift in how we understand biological complexity. Recently, we sat down with Dr. Maria Montes-Bayón, a leading professor of analytical chemistry at the University of Oviedo and a key researcher at the Institute for Sanitary Research of Asturias, to discuss the physical, technical, and operational hurdles of single-cell inductively coupled plasma mass spectrometry (sc-ICP-MS). From her vantage point at the intersection of biotechnology and analytical science, she shares insights on the technique's journey from academic specialization to potential clinical adoption.
The Physical Frontier: Stability and Transport
One of the most immediate challenges in single-cell analysis is ensuring the sample survives the journey to the plasma. Unlike robust bacterial or yeast cells, eukaryotic cells are notoriously delicate.
"Before introducing the cells into the plasma, you need to ensure that they remain stable," Montes-Bayón explains. "For this, you shouldn't dilute them in anything that provokes the breakage of the cell membrane. You need to preserve them in good conditions, typically in a buffer and cooled to 4℃ before introduction."
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
Beyond stability, achieving high transport efficiency is critical for reliable data. Researchers aim to introduce as many cells as possible into the ICP to ensure robust counting statistics. While conventional sample introduction systems often achieve efficiencies as low as 10%, optimized systems can reach 70% to 80%.
"You need to force cells to pass through very narrow capillaries to get into your spray chamber," she notes. "In normal sample introduction, the internal diameters are broader. This means you have a higher chance of getting doublets or triplets of cells together because they tend to attach. We try to avoid that."
Hardware and the Speed of Ions
Once a cell successfully navigates the introduction system and reaches the plasma, the analytical challenge shifts from fluid dynamics to the sheer speed of atomic events. The transition from a single biological entity to a detectable signal is nearly instantaneous, creating a significant "speed limit" for standard instrumentation.
The core of this analytical challenge is governed by the laws of physics: the ion plumes generated by a single cell are incredibly brief, lasting approximately 500 𝜇s.
In standard sequential quadrupole systems, this speed limit means researchers can only monitor one isotope per cell event. "This is very unfortunate, because you could get an elemental fingerprint of all the constitutive elements if you could jump from one isotope to the next for every individual cell. Unfortunately, you cannot do that simultaneously with quadrupoles," Montes-Bayón points out.
To overcome this, the field is moving toward time-of-flight (TOF) mass analyzers. "TOF mass analyzers are the way out of this because they allow for faster scanning," she advises. However, there is a trade-off. Some specialized TOF-ICP-MS systems gain sensitivity by narrowing their mass scanning range (typically 75 to 209 isotopes). While excellent for clinical immunophenotyping, this range excludes essential lower-mass elements, including iron (Fe), copper (Cu), zinc (Zn), and phosphorus (P), highlighting the "gain on one side, lose on the other" reality of current hardware.
Unmasking Heterogeneity: The "Fruit Juice" Analogy
The pursuit of single-cell data is essential due to cellular heterogeneity, a critical factor in cancer research and the investigation of metallo-drugs such as cisplatin. Montes-Bayón uses a vivid analogy to explain why the "average" result from bulk analysis is no longer sufficient for modern medicine.
"When you take fruit juice, you taste the flavor of all the fruits combined. But what you need to know is how many cherries, apples, bananas, or strawberries you had in there to truly understand or reproduce that flavor."
In chemotherapy, bulk analysis yields an average result that often masks the presence of two distinct populations. A bulk result might suggest a moderate uptake of a drug across a tumor, while single-cell analysis reveals that a specific subpopulation is completely resistant.
"Analyzing things at the individual level gives you hints on the reasons for drug resistance," Montes-Bayón asserts. "The fastest way to detect a change in response is to see when just a few cells have changed, rather than waiting until the entire culture has shifted."
The Metabolism Limitation
A recurring question for pharma scientists is whether the metal detected by ICP-MS represents the active drug or a metabolite. Montes-Bayón is candid about the current limitations of the technique.
"We cannot achieve this information by single-cell ICP-MS alone. The high-temperature plasma obliterates the actual molecular structures. We just know the cell and the drug are together. We don't know if it's the precursor drug or if it has been metabolized," she admits.
To address this for drugs such as cisplatin, her lab performs subsequent bulk analysis of the extracted target molecules. "We extract DNA from cells and monitor if platinum is there. If platinum is attached to DNA, it indicates that the compound has been metabolized and directed to the target molecule. You need these additional experiments to prove what the single-cell analysis is seeing," she advises.
Complementary Strengths: Protein vs. RNA
Montes-Bayón views sc-ICP-MS as a vital complement to tests like PCR, rather than a replacement.
"PCR measures at the DNA or RNA level, so you are not measuring the biomarker itself in its protein form, but just the precursors," she explains. "With single-cell ICP-MS, you are measuring at the protein level. You know the protein has actually been expressed."
Furthermore, sc-ICP-MS offers distinct advantages over traditional flow cytometry: elimination of spectral overlap and absolute quantification. "ICP-MS analysis provides absolute metal concentrations, which can be correlated with biomarker concentrations. This is an additional set of information that is very helpful for biochemical studies," Montes-Bayón notes.
The Road to Clinical Pathology
For sc-ICP-MS to transition from specialized academic environments into standard clinical pathology, the field must focus on standardizing performance and bridging existing technical gaps. Dr. Montes-Bayón believes that the path forward involves rigorous cross-validation and the refinement of high-sensitivity hardware.
"We should aim to compare our data across different systems to see if we can achieve the same standard as established clinical tools," she observes. "By focusing on elements where different instrument mass ranges overlap, we can provide more comprehensive information and better sensitivity. This will cover some of the gaps that sc-ICP-MS still faces."
The future lies in the convergence of rigorous analytical quantification and the high-throughput, user-friendly requirements of a clinical diagnostic setting. As standardization improves, sc-ICP-MS is poised to become a staple for precision medicine.
